Newsroom

News Releases

Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals

-- Effort Increases Awareness of Pain Management with Non-Opioid Treatments and Techniques as Foundation to Reduce Opioid Use --

STAINES-UPON-THAMES, United Kingdom, June 21, 2017 /PRNewswire/ -- Mallinckrodt Pharmaceuticals, a leading global specialty pharmaceutical company, and the Massachusetts Health & Hospital Association (MHA) today announced the release of the Pain Stewardship ProgramTM (PSP) for providers and clinical staff.

Mallinckrodt logo

Mallinckrodt logo

Developed in collaboration with a multidisciplinary team of expert advisors, the mission of the PSP is to educate hospital stakeholders on multimodal analgesia (MMA)-based acute pain management to support improvements in in-hospital opioid use, length of stay (LOS) and satisfaction with treatment. The program provides evidence-based, educational pain management tools to help assess current hospital protocols and identify areas for improvement.

With MMA, non-opioid treatments and techniques are the foundation of acute pain management. MMA combines two or more analgesic agents or techniques that use different mechanisms to provide pain relief with fewer opioids. Non-opioid treatments – both pharmacologic and non-pharmacologic – as the foundation of acute pain management, when used in combination with opioids, may reduce opioid doses needed to effectively manage patient pain.1 Additional benefits of MMA include reduced risk of opioid-related adverse drug events (ADEs)1,2,3,4; shorter LOS5; less pain during rest and activity6,7; and improved patient satisfaction with treatment. 8

MHA's Substance Use Disorder Prevention and Treatment Task Force (SUDPTTF) was created to assist hospitals, affiliated physician practices and other care providers with operational and clinical best practices to address a growing opioid crisis. A smaller workgroup of the MHA Task Force, led by John M. Connolly M.D., Chairman of the Department of Anesthesia and VPMM at BIDPH and James A Berghelli, R.Ph and MS, Director of Clinical Integration at Beth Israel Deaconess Hospital – Plymouth, worked with Mallinckrodt to develop the PSP materials.

"Massachusetts hospitals and clinicians have made significant improvements in reducing overall opioid usage as well as educating our patients on associated risk factors and proper disposal of opioids. Our providers are also committed to developing alternative pain management practices that improve patient satisfaction, safety and outcomes," said Patricia M. Noga, PhD, RN, MHA's Vice President of Clinical Affairs and the Chair of the MHA SUDPTFF. "The Pain Stewardship Program emphasizes non-opioid analgesics and techniques as first-line therapy that is a balanced acute pain management practice, which we believe will assist in addressing the opioid crisis impacting our communities."

"The Pain Stewardship Program provides educational resources that address an important priority for hospitals – an MMA approach for acute pain to help reduce use of opioids," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, Mallinckrodt. "As part of our commitment to safe and effective acute pain management, Mallinckrodtwill work collaboratively with hospital stakeholders to provide educational resources about best practices, and increase provider and patient education on acute pain management that can help improve patient outcomes and satisfaction."

Through the Pain Stewardship Program, acute pain management resources and tools will be available via www.PainStewardship.com, to help institutions build internal consensus, implement recommendations, educate surgical patients and assess both patient acute pain and clinical risk factors. These resources and tools include:

  • Acute pain management guide and published analgesic recommendations;
  • Patient education brochure and hospital checklists;
  • Videos;
  • MMA infographic; and
  • Speaker resources.

ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. On its website or in press releases and other communications, Mallinckrodt may provide links or references to other sites, but Mallinckrodt has no responsibility for the content of such other sites.

ABOUT THE MASSACHUSETTS HEALTH & HOSPITAL ASSOCIATION
The Massachusetts Health & Hospital Association (MHA) is a voluntary, not-for-profit organization comprised of hospitals and health systems, related organizations, and other members with a common interest in promoting the good health of the people of the Commonwealth. The MHA Substance Use Disorder Prevention and Treatment Task Force developed provider focused strategies to help address the high incidence of opioid misuse that affects our communities. Copies of MHA-provided resources are available at: http://www.mhalink.org/sudpttf.

CONTACTS

Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com

Catherine S. Bromberg
Senior Director, External Communications
Massachusetts Health & Hospital Association
781-262-6027
cbromberg@mhalink.org

References

1 Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg. 1993;77(5):1048-1056.
2 White PF. Multimodal analgesia: its role in preventing postoperative pain. Curr Opin Investig Drugs. 2008;9(1):76-82.
3 Garimella V, Cellini C. Postoperative pain control. Clin Colon Rectal Surg. 2013;26(3):191-196.
4 Mann C, Pouzeratte Y, Boccara G, et al. Comparison of intravenous or epidural patient-controlled analgesia in the elderly after major abdominal surgery. Anesthesiology. 2000;92(2):433-441.
5 Michelson JD, Addante RA, Charlson MD. Multimodal analgesia therapy reduces length of hospitalization in patients undergoing fusions of the ankle and hindfoot. Foot Ankle Int. 2013;34(11):1526-1534.
6 Fu PL, Xiao J, Zhu YL, et al. Efficacy of a multimodal analgesia protocol in total knee arthroplasty: a randomized, controlled trial. J Int Med Res. 2010;38(4):1404-1412.
7 Sivrikoz N, Koltka K, Güresti E, Büget M, Sentürk M, Özyalçın S. Perioperative dexketoprofen or lornoxicam administration for pain management after major orthopedic surgery: a randomized, controlled study. Ağri. 2014;26(1):23-28.
8 Skinner HB. Multimodal acute pain management. Am J Orthop. 2004;33(suppl 5):5-9.

 

SOURCE Mallinckrodt Pharmaceuticals

Related Links

http://www.mallinckrodt.com